MRI, Biopsy and PSA Before Prostate HIFU: How the Workup Decides Whether Focal Therapy Fits

The letter arrives on a Tuesday. A slightly raised PSA, a request to come back, and a man who has never spent a minute thinking about his prostate now spends every minute thinking about it. By the weekend he has read about HIFU, a treatment that uses focused sound waves to heat and destroy a small area of the gland, and it sounds like the answer he wants: no surgery, no weeks of radiation, keep the rest.

What he has not yet read is that the treatment is the last decision in a long chain, and the chain is built from MRI and biopsy before prostate HIFU is ever offered. Focal therapy only makes sense if you know exactly where the cancer is, and just as importantly, where it is not.

That is what this explainer covers: what each test measures, how the results are read together, who is usually offered focal HIFU, who is asked to wait, and what the honest evidence says about the weeks and years afterward.

Why MRI and biopsy before prostate HIFU decide more than the machine does

Focal therapy is a simple idea with a demanding precondition. Instead of removing or irradiating the whole prostate, the clinician treats only the part that contains the cancer and leaves the rest alone, hoping to spare the nerves that control erections and the muscles that control urine. The precondition is knowledge. You cannot treat part of an organ unless you trust your map of it.

That map is drawn by three instruments. PSA, a protein made by prostate cells and measured in a blood test, tells you how much suspicion there is. Multiparametric MRI, a scan that combines several types of images of the gland, tells you where the suspicion sits. Biopsy, the removal of tiny tissue cores with a needle, tells you what the suspicious area actually is and whether the quiet-looking parts of the gland are truly quiet.

Here is the opinion that runs through this article: for focal HIFU, the biopsy’s most valuable job is often not confirming the tumor the MRI already found. It is proving that the other side of the gland is clear enough to leave untreated. A biopsy that samples only the bright spot on the scan answers half the question.

It is worth knowing from the outset that HIFU is not a standard first-line treatment everywhere. The NHS describes it as a treatment that is not widely available, mainly offered in specialist centers or as part of clinical trials, because long-term evidence on how it compares with surgery and radiotherapy is still limited. That context shapes how carefully the workup is done. When a treatment is newer, the selection has to be older and stricter.

What PSA levels before HIFU can and cannot tell you

PSA is where nearly every prostate story begins, and it is also the most misunderstood number in the chain. A raised level does not mean cancer. According to MedlinePlus, PSA can rise with a benign enlarged prostate, a urinary or prostate infection, recent ejaculation, vigorous cycling, and even a recent digital rectal exam. A low level does not rule cancer out either, because some cancers make little PSA.

So what does PSA do in the run-up to focal therapy?

• It opens the door. A persistently raised or rising PSA is the usual reason a man ends up having an MRI at all.
• It sets the baseline. After HIFU, the prostate is not removed, so PSA will not fall to undetectable the way it can after surgery. The team compares later readings with the pre-treatment value and with the lowest point reached afterward, sometimes called the nadir.
• It adds a risk signal. Clinicians often look at PSA density, the PSA level divided by the prostate volume measured on MRI. A high density makes hidden or more extensive cancer more likely.
• It can close the door. A very high PSA, or one climbing quickly, raises the chance that disease extends beyond a single focus or beyond the gland, which usually shifts the conversation away from focal treatment toward whole-gland options or further staging scans.

No single cut-off decides eligibility, and you will find different thresholds in different consensus statements. What PSA cannot do is locate anything. It is a smoke alarm, not a floor plan. That job belongs to the scan.

Is it recommended to get an MRI before a prostate biopsy?

In many health systems, yes, and the shift happened because of a specific study. The PROMIS trial, published in The Lancet, gave 576 men with a raised PSA a multiparametric MRI and then two biopsies: the standard ultrasound-guided biopsy and a detailed template biopsy that sampled the entire gland as a reference. MRI detected 93 percent of clinically significant cancers, compared with 48 percent for the standard biopsy alone. The authors estimated that using MRI as a triage test could allow about a quarter of men to avoid an immediate biopsy while also reducing the diagnosis of insignificant cancers.

The NHS now describes MRI as the usual first test after a raised PSA, with biopsy following only if the scan raises concern. That order matters for focal therapy in a second way: the scan is not just a filter, it is the targeting map for the needle and later for the treatment probe.

Radiologists report the scan with a PI-RADS score, a five-point scale describing how likely an area is to contain clinically significant cancer. A score of 1 or 2 means low suspicion, 3 is equivocal, and 4 or 5 means high suspicion. The report also gives the prostate volume, the location and size of any lesion, and whether the capsule, the gland’s outer wall, looks intact.

Two cautions. First, MRI still misses some cancers: in PROMIS, a negative scan still left a small chance of significant disease, so a normal MRI with a high PSA density may still lead to biopsy. Second, image quality varies with scanner, protocol and reader experience. If you are being assessed for focal treatment, ask whether the scan was a full multiparametric study and whether it was read by someone who reports prostate MRI regularly.

What percentage of prostate biopsies turn out to be cancer, and which biopsy route is used

The honest answer is that it depends heavily on why you are being biopsied. In PROMIS, where every participant had a raised PSA and every gland was sampled thoroughly, roughly 4 in 10 men had clinically significant cancer, and more had lower-grade disease. Among men with a low PI-RADS score and low PSA density, the proportion is far smaller; among men with a PI-RADS 5 lesion, it is far higher. A single national percentage would be misleading, so treat any headline figure with suspicion.

How the biopsy is done shapes what it can tell the focal-therapy team.

• Targeted cores are aimed at the MRI lesion, either by fusing the MRI onto live ultrasound with software or by the clinician mentally translating the MRI position, sometimes called cognitive targeting.
• Systematic cores sample set regions across the gland regardless of what the scan shows. These are what reveal cancer in the MRI-invisible zones, and they are the cores that protect against leaving disease untreated.
• Template or saturation biopsy samples the whole gland through a grid, giving the most complete map. Some focal programs ask for this level of detail before committing to treating only one side.

The needle can enter through the rectal wall (transrectal) or through the skin between the scrotum and anus (transperineal). The Mayo Clinic notes that infection is a recognized risk of prostate biopsy and that antibiotics are given beforehand; the transperineal route avoids passing through the bowel and is increasingly preferred for that reason. Either way, expect a local anesthetic or, for larger template procedures, a general or spinal one.

For someone hoping for focal treatment, the practical point is this: a biopsy with targeted cores only may confirm the cancer but cannot confirm that it is alone.

Gleason grade groups and what clinically significant really means

The biopsy report comes back with a vocabulary of its own. A pathologist looks at how much the cancer cells still resemble normal prostate glands and assigns a Gleason score, built from the two most common patterns seen. Those scores are now grouped into five grade groups, from 1 (least aggressive) to 5 (most aggressive), a system the NHS describes on its diagnosis pages.

Where you land in that system is the single biggest driver of whether focal HIFU is even discussed.

• Grade group 1 cancers grow slowly and are usually managed with active surveillance, a program of PSA checks, repeat MRI and repeat biopsy rather than treatment. Most focal-therapy consensus statements consider treating these an over-treatment.
• Grade group 2, and selected grade group 3 cancers are the usual territory for focal approaches, provided the disease is localized to one region.
• Grade groups 4 and 5 carry a higher risk of spread and of microscopic disease elsewhere in the gland, and they are generally directed to whole-gland treatment, sometimes with additional therapy.

The phrase clinically significant is a research definition rather than a feeling. In PROMIS it meant a Gleason score of 4+3 or higher, or a core containing 6 mm or more of cancer. Different studies use slightly different thresholds, which is one reason quoted detection rates vary between papers.

Two other lines on the report matter for planning. The number of positive cores and their location tell the team how large and how confined the target is. And any mention of the cancer reaching the edge of a core taken near the capsule raises the question of whether the disease is truly contained, which the team may pursue with further imaging before any focal plan is drawn.

How focal HIFU actually works, step by step

Sunlight through a magnifying glass is the everyday image. Ordinary ultrasound waves pass through tissue harmlessly; HIFU concentrates them onto a point a few millimeters across, where the energy becomes heat intense enough to coagulate tissue in seconds. Move the focal point systematically across a planned volume and you ablate, that is destroy, the region while the tissue outside it stays cool.

On the day, the procedure usually looks like this. You are given a general or spinal anesthetic. A probe is placed in the rectum, the same position as a biopsy ultrasound, and the prostate is imaged live. The clinician overlays the treatment plan built from the MRI and biopsy map, then defines the zone to be treated, typically the tumor plus a safety margin. Depending on where and how large the cancer is, the plan may cover one lobe (often called hemi-ablation), a quadrant, or a smaller defined area. The device then delivers hundreds of small overlapping pulses. The whole session commonly takes a few hours, with the exact length set by the size of the zone.

Because the prostate swells after heating, a urinary catheter, a soft tube draining the bladder, is placed and left in for a period your team will specify. Most people go home the same day or after one night.

The mechanism explains the risks. Heat near the urethra can cause burning, urgency and later scarring. Heat near the neurovascular bundles, the nerve and vessel cords along each side of the gland that support erections, can affect sexual function. Heat near the rectal wall carries a rare risk of a fistula, an abnormal channel between the urethra and rectum. The NHS lists urinary problems and erectile dysfunction as recognized side effects and describes fistula as uncommon. A well-drawn map is what keeps the treated zone away from the structures that matter.

Who is a candidate for focal HIFU, and who is usually asked to wait

There is no universal eligibility form, and criteria differ between programs and trials. That said, the pattern across published consensus statements is consistent enough to describe.

Focal HIFU is usually considered when the workup shows all of the following at once: a cancer in grade group 2 or selected grade group 3; a single lesion visible on MRI whose position matches the biopsy findings; systematic or template cores showing no significant cancer in the parts of the gland that would be left untreated; a tumor located where the ultrasound beam can safely reach it; a PSA that is not unusually high for the volume of the gland; and no evidence on imaging that the cancer has moved beyond the capsule or to lymph nodes or bone.

People are often steered toward other paths when:

• The cancer is grade group 1, where active surveillance is generally advised instead of any treatment.
• Significant cancer is found in more than one region, or the MRI and biopsy disagree about where the disease is.
• The grade is 4 or 5, or staging suggests spread.
• The lesion sits far forward or high in the gland, out of the probe’s comfortable reach, or the gland is very large.
• Dense calcifications lie in the path of the beam and would scatter it.
• An MRI cannot be performed, for example because of certain implanted devices, which removes the map the treatment depends on.
• The prostate has previously been irradiated. HIFU after radiation exists as salvage treatment, but it is a different decision with a different risk profile.

Being asked to wait is not a refusal. Often it means a repeat MRI, additional cores, or a period of surveillance so the team can be confident before treating part of an organ and leaving the rest. The decision rests with a multidisciplinary team, usually including urology, radiology and pathology, and with you.

MRI, biopsy and PSA before prostate HIFU: what each test decides

Seen side by side, the tests are less a sequence than a set of questions, each with a blind spot that another test covers. The table below is a summary; your own team may add or omit steps based on your results.

Test	What it measures	Question it answers before focal HIFU	Main limitation
PSA and PSA density	A protein in the blood, adjusted for gland volume	How much suspicion is there, and what is the baseline for follow-up?	Rises with benign causes; cannot locate anything
Multiparametric MRI (PI-RADS)	Structure, water movement and blood flow in the gland	Where is the lesion, how big is it, is the capsule intact?	Misses some cancers; quality depends on scanner and reader
MRI-targeted biopsy	Tissue from the suspicious area	What grade is the visible target?	Says nothing about the rest of the gland
Systematic or template biopsy	Tissue from set regions across the gland	Is the untreated side clear enough to leave alone?	More cores, more discomfort, more sampling time
Staging imaging (bone scan, CT, or PSMA PET where used)	Disease outside the prostate	Has anything spread that would make focal treatment pointless?	Not needed for everyone; use is guided by grade and PSA

Reading the table, the logic of focal therapy becomes clearer. PSA opens the inquiry. MRI draws the map. Targeted biopsy labels the landmark. Systematic biopsy checks the empty spaces. Staging confirms the borders of the map are the borders of the disease.

Notice, too, that the item most often skipped in a rushed pathway, the systematic sampling, is the one that guards against the specific failure mode of focal treatment: leaving cancer behind on purpose because nobody looked for it. If your workup consisted of a scan and a handful of targeted cores, it is reasonable to ask whether more sampling is needed before a focal plan is finalized.

How long does it take for a prostate to heal after a biopsy?

Faster than most people fear, and slower than most people would like. The NHS advises that after a prostate biopsy you may notice blood in your urine, in your semen or in your stool for a few weeks, and the Mayo Clinic notes that blood in semen in particular can persist for several weeks as the tiny needle tracks heal. Mild soreness and a bruised feeling in the perineum, the area between the scrotum and anus, are common for the first days, especially after a transperineal procedure.

What you will usually be told:

• Drink normally, do not strain, and expect the first urine after the biopsy to be pink or rusty.
• Finish any antibiotic course exactly as prescribed; do not adjust it yourself.
• If you take an anticoagulant or antiplatelet medicine, your team will have given you specific instructions before the procedure. Never restart or stop these on your own.
• Light activity is usually fine within a day or two; heavy lifting and cycling are often deferred for a short period your team will specify.

For someone heading toward focal treatment, healing has a second meaning. A biopsy causes bruising and small areas of bleeding inside the gland that show up on MRI and can mimic or obscure a tumor. If a repeat or higher-quality MRI is needed for planning, your team may schedule it after the tissue has settled rather than immediately. The same applies to the treatment itself: HIFU relies on clear ultrasound images and an accurate MRI overlay, and swelling from a recent biopsy can distort both. Ask how the timing of your scan, biopsy and treatment has been sequenced and why.

Results typically take days to a couple of weeks depending on the laboratory and whether additional stains are needed. That waiting period is a normal part of the process, not a sign that something is wrong.

What the days and weeks after focal HIFU usually look like

The first thing most people notice is the catheter, and the second is how little pain there is compared with what they imagined. Focal HIFU involves no incision, so the recovery is dominated by the urinary tract’s reaction to heat rather than by wound healing.

In the early days, expect the catheter to remain in place while swelling subsides; your team will tell you when it comes out and what to watch for once it does. After removal, burning, urgency, frequency and a weaker stream are common, and it is normal to pass small amounts of blood and soft tissue debris as the treated area sloughs and clears through the urethra. Some men need a temporary medicine to relax the bladder outlet; if one is suggested, the choice and duration sit with the prescribing clinician.

Over the following weeks, urinary symptoms usually settle gradually rather than overnight. Erectile function is more variable: it depends on how close the treated zone came to the neurovascular bundles and on your function beforehand, and it can continue to change for months. Ejaculate volume often falls because part of the gland that produces seminal fluid has been treated.

The follow-up schedule is where focal therapy differs most from surgery. Your team will typically arrange:

• A PSA check to establish the post-treatment nadir, then regular checks after that.
• A follow-up MRI at intervals to look at the treated zone and the untreated tissue.
• Frequently, a planned repeat biopsy of the treated area, sometimes of the whole gland, because imaging alone cannot confirm that no viable cancer remains.

That last point surprises people. A repeat biopsy after focal treatment is not a sign of failure; in many protocols it is a standard part of the plan, and the NHS is explicit that long-term outcomes for HIFU are still being studied. Knowing the schedule up front makes it easier to live with.

Does prostate cancer return after HIFU? What follow-up actually shows

This is the question behind every other question, and it deserves a plain answer: yes, it can, and understanding why is more useful than any single number.

Recurrence after focal treatment happens in two distinct ways. The first is residual cancer in the treated zone, where the heat did not fully destroy the target, often because of an imprecise margin or a tumor that extended further than the images suggested. The second is cancer in the untreated tissue, either a focus that was present but not detected at the time, or a new one that developed later. The prostate is still there, and it is still a prostate.

The size of the risk is where honesty requires restraint. The NHS states that there is not yet enough long-term evidence to know how HIFU compares with surgery or radiotherapy, and most published outcomes come from single-center or multi-center cohort studies rather than randomized trials with long follow-up. Because different programs define failure differently, using different PSA thresholds, imaging criteria and biopsy protocols, quoting one figure would give you a false sense of precision. Ask your team what their own definitions and follow-up findings are.

What the evidence does support is the logic of the workup. Series in which men were selected with complete MRI and systematic biopsy mapping report fewer surprises in the untreated tissue than series that relied on targeted cores alone. In other words, the quality of the map before treatment is one of the strongest predictors of what the follow-up biopsy finds.

If cancer is found after HIFU, options generally remain open: repeat focal treatment, whole-gland surgery, radiotherapy, or surveillance if the finding is low grade. Surgery after HIFU can be technically more demanding because of scarring, which is one more reason teams are cautious about who they treat focally in the first place.

What people often get wrong about the pre-HIFU workup

Some misunderstandings show up in almost every consultation. Correcting them early saves distress later.

“The MRI found the cancer, so I already have a diagnosis.” MRI finds areas of suspicion. Only tissue under a microscope confirms cancer and assigns a grade, and grade is what determines whether focal treatment is even on the table.

“My MRI was normal, so I am clear.” PROMIS showed that MRI is a strong test, not a perfect one; a small proportion of significant cancers were missed. A normal scan with a high PSA density or a rising PSA still warrants a conversation about biopsy.

“Biopsy spreads the cancer.” This fear persists despite decades of practice. Mainstream sources, including the Mayo Clinic, list bleeding, infection and temporary urinary difficulty as the biopsy risks, not tumor seeding.

“Focal therapy has no side effects.” It generally has fewer than whole-gland treatment, but urinary symptoms and changes in sexual function are recognized, and fistula, though rare, is serious. Anyone who tells you the risk is zero is selling something.

“HIFU is for anyone who wants to avoid surgery.” It is for a specific pattern of disease. Wanting it is not the same as being suitable for it, and a good team will decline to treat when the map does not support it.

“One biopsy is enough forever.” Focal treatment commits you to ongoing surveillance of the untreated tissue, which usually includes further MRI and, in many protocols, further biopsy.

“A low-grade result means I should treat it now before it gets worse.” Grade group 1 disease is generally managed with active surveillance, and treating it focally exposes you to side effects for a cancer that may never have needed treatment.

Questions to ask your care team before agreeing to focal HIFU

Bring these to the consultation and write down the answers. The aim is not to test the team but to understand the map you are about to be treated from.

• Was my MRI a full multiparametric study, and was it reported by a radiologist who regularly reads prostate MRI? What was my PI-RADS score and lesion size?
• Which biopsy approach did I have: targeted only, targeted plus systematic, or template? How many cores were taken from the side of the gland you plan to leave untreated?
• What is my grade group, how many cores were positive, and do the biopsy findings match the MRI location?
• What is my PSA density, and does it change how confident you are that the disease is confined to one region?
• Do I need staging imaging before we decide, and if not, why not?
• Would active surveillance be a reasonable option for me instead of any treatment right now?
• How much of the gland do you plan to treat, and how close will the treated zone come to the urethra, the rectal wall and the nerves that support erections?
• What urinary and sexual side effects have you seen in patients with a similar plan, and how were they managed?
• What is the follow-up schedule: how often will I have PSA checks, MRI and repeat biopsy, and what result would prompt further treatment?
• If cancer is found again after HIFU, what options would still be available to me, and does having had HIFU make any of them harder?
• Is this treatment being offered within a clinical trial or registry, and if so, what does that involve?

A team that welcomes these questions is a good sign. So is a team willing to say that focal therapy is not the right fit and to explain what is.

When to call your doctor during the workup and after HIFU

Most of the workup is uneventful, and most recoveries after focal HIFU are dominated by nuisance symptoms rather than danger. A few signs, however, should never wait for the next scheduled appointment.

After a prostate biopsy, contact your team the same day, or seek urgent care, if you notice:

• A fever, chills or shaking, which the Mayo Clinic and NHS both flag as possible signs of infection after biopsy. Infection can progress quickly to sepsis, a life-threatening reaction, so this is an emergency, not a wait-and-see.
• Inability to pass urine, or passing only small amounts with a painfully full bladder.
• Heavy or persistent bleeding from the rectum, or urine that is thick with clots rather than tinged pink.
• Worsening pain rather than improving pain over the first days.

After HIFU, call promptly if you experience:

• Fever or chills, especially while a catheter is in place or soon after it is removed.
• A catheter that stops draining, or an inability to urinate after it comes out.
• Severe pain in the pelvis or rectum, or pain on sitting that steadily worsens.
• Urine leaking from the rectum, or stool or gas passing through the urethra. These are signs of a possible fistula, which is rare but needs immediate assessment.
• Confusion, drowsiness, a racing heart or breathlessness alongside fever; call emergency services.

Between visits, a new and persistent change in your urinary pattern, or PSA results you do not understand, are reasons to get in touch rather than to search online. Your treating team knows your map, your grade and your plan, and every decision about further tests or treatment belongs to that conversation.

Frequently asked questions

Is it recommended to get an MRI before a prostate biopsy?

In most modern pathways, yes. The NHS lists MRI as the usual first test after a raised PSA, and the PROMIS trial found MRI detected 93 percent of clinically significant cancers versus 48 percent for standard biopsy alone. The scan can spare some men a biopsy and, for those who need one, provides the target the needle and any later focal treatment are aimed at.

Does prostate cancer return after HIFU?

It can, either in the treated zone if the ablation margin was incomplete or in the untreated tissue where cancer was missed or developed later. The NHS notes long-term evidence is still limited, and definitions of recurrence vary between studies, so no single percentage is reliable. Follow-up with PSA, MRI and often repeat biopsy is designed to catch this early, and further treatment options usually remain.

How long does it take for a prostate to heal after a biopsy?

Most discomfort settles within days, but the NHS advises that blood in urine, semen or stool can persist for a few weeks, and the Mayo Clinic notes blood in semen may last several weeks. Internal bruising can also affect MRI appearances for a while, which is why a planning scan or focal treatment may be scheduled after the tissue has settled.

What percentage of prostate biopsies turn out to be cancer?

It depends on why the biopsy was done. In the PROMIS trial, where every man had a raised PSA and thorough sampling, roughly 4 in 10 had clinically significant cancer, with more showing lower-grade disease. Men with low PI-RADS scores and low PSA density have a much smaller chance; men with a PI-RADS 5 lesion have a much higher one. Ask for your own estimate.

What PSA levels before HIFU are considered suitable for focal therapy?

There is no universal cut-off. Teams look at the PSA level together with prostate volume, calculating PSA density, and at how it has changed over time. A very high or rapidly rising PSA raises the chance of disease beyond a single region or outside the gland, which usually shifts discussion toward whole-gland treatment or staging scans. Your team will explain how your value fits their criteria.

Who is a candidate for HIFU as focal treatment?

Typically someone whose workup shows a grade group 2, or selected grade group 3, cancer confined to one MRI-visible region, with systematic biopsy cores showing the rest of the gland is clear of significant disease, no sign of spread, and a tumor the ultrasound probe can safely reach. Criteria vary between programs and trials, and the final decision sits with a multidisciplinary team.

Can I have HIFU without a biopsy if my MRI shows a lesion?

No. MRI shows suspicion, not diagnosis, and it cannot provide the grade group that determines whether focal treatment is appropriate at all. Treating on imaging alone risks treating a benign area or, more seriously, under-treating a high-grade cancer that needed a different approach. Every mainstream pathway requires tissue confirmation before any prostate cancer treatment, focal or whole-gland.

Why do I need systematic cores if the MRI target has already been biopsied?

Because focal therapy deliberately leaves part of the gland untreated, and the only way to know that part is safe to leave is to sample it. Targeted cores confirm what the scan saw; systematic or template cores look for what it did not. PROMIS showed MRI misses a small share of significant cancers, and those missed areas are exactly where recurrence after focal treatment would come from.

Do I need a bone scan or PSMA PET before HIFU?

Not everyone does. Staging imaging is generally guided by grade group and PSA level, and for lower-risk localized disease it is often not required. Where the grade is higher or the PSA is unusually high for the gland size, a scan to look for spread to lymph nodes or bone may be requested, because focal treatment makes no sense if disease exists outside the prostate. Your team decides based on your results.

What happens if the biopsy after HIFU shows cancer again?

It depends on the grade and location. Low-grade findings may be monitored. Significant cancer in the treated zone might be managed with repeat focal treatment, while disease elsewhere or higher-grade disease usually prompts discussion of surgery or radiotherapy. Surgery after HIFU can be more technically demanding because of scarring, which is one reason teams select focal candidates carefully and plan follow-up biopsy in advance.

References

• Prostate cancer: Diagnosis (NHS)
• Prostate cancer: Treatment (NHS)
• Prostate-Specific Antigen (PSA) Test (MedlinePlus)
• Screening for Prostate Cancer (CDC)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.